Author

S Menjoge

Observed names: MENJOGE S, S. Menjoge, S.S. Menjoge, Shailendr Menjoge

Institution: Boehringer Ingelheim (United States)

Observed institutions: Dartmouth–Hitchcock Medical Center, Boehringer Ingelheim (Germany), University of California, Los Angeles, Uplift, Boehringer Ingelheim (United States)

OpenAlex ID: A5111962760

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

2002 · R. Casaburi, D.A. Mahler, et al. · European Respiratory Journal · 881

One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium

2004 · A. Anzueto, D. Tashkin, et al. · Pulmonary Pharmacology & Therapeutics · 119

Tolerance to bronchodilating effects of salmeterol in COPD

2003 · J.F Donohue, S Menjoge, et al. · Respiratory Medicine · 87

Estudo de quatro anos de tiotrópio na doença pulmonar obstrutiva crónica (estudo UPLIFT)

2009 · D. Tashkin, B. Celli, et al. · Revista Portuguesa de Pneumologia · 21

Responder Analyses for Treatment Effects in COPD Using the St George’s Respiratory Questionnaire

2017 · Paul W. Jones, Heather Gelhorn, et al. · Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · 12

Machine Learning Models for Predicting Mortality in Idiopathic Pulmonary Fibrosis (IPF) Patients

2019 · Z. Zhu, J. Geng, et al. · American Journal of Respiratory and Critical Care Medicine

Predicting mortality in idiopathic pulmonary fibrosis (IPF) patients treated with Nintedanib

2019 · J Behr, W Tang, et al. · Pneumologie

Estudo de quatro anos de tiotrópio na doença pulmonar obstrutiva crónica (estudo UPLIFT) A 4-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial)

2009 · D Tashkin, B Celli, et al. · White Rose Research Online (University of Leeds, The University of Sheffield, University of York)

Works count: 9

Citation count: 1,120

H-index: 5

I10-index: 5